B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

B. Riley Securities analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $83.